Opus Point Partners Management’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Opus Point Partners Management’s Portfolio MNTA Stock Details MNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-60,000	Closed	-$912K	–	71
2015 Q1	$912K	Sell	60,000 -10,000	-14%	-$130K	0.76%	33
2014 Q4	$843K	Buy	+70,000	New	+$800K	0.83%	35

Other funds holding MNTA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $2.41B AUM 286.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $7.56B AUM 44.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Opus Point Partners Management's MNTA Position: Q2 2015 in Review

Opus Point Partners Management sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q2 2015, closing a stake of 60,000 shares — an estimated $912K sold.

Opus Point Partners Management first reported a position in MNTA in Q4 2014 and held it in 2 quarters. The position peaked at $912K in Q1 2015. 162 funds tracked by Wall St. Rank hold MNTA as of Q2 2015.

Opus Point Partners Management reported no remaining Momenta Pharmaceuticals, Inc. position as of Q2 2015 after selling out during the quarter.
Opus Point Partners Management sold 60,000 Momenta Pharmaceuticals, Inc. shares in Q2 2015, an estimated $912K.
Opus Point Partners Management first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2014 and held it in 2 quarters.
Opus Point Partners Management's Momenta Pharmaceuticals, Inc. position peaked at $912K in Q1 2015.
162 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q2 2015.

Based on Opus Point Partners Management's 13F filing for Q2 2015, filed 14 Aug 2015.